Open AccessPatterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership
Author(s) -
Lesley-Ann Miller,
Stephen Stemkowski,
Kim Saverno,
Daniel C. Lane,
Zhuliang Tao,
Michelle D. Hackshaw,
Bryan A. Loy
Publication year - 2016
Publication title -
journal of managed care and specialty pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.126
H-Index - 63
eISSN - 2376-1032
pISSN - 2376-0540
DOI - 10.18553/jmcp.2016.22.3.219
Subject(s) - medicine , discontinuation , medical prescription , renal cell carcinoma , systemic therapy , specialty , medicare advantage , population , prescription drug , regimen , cancer , retrospective cohort study , health care , family medicine , breast cancer , environmental health , economics , pharmacology , economic growth
Several systemic therapies are now approved for first- and second-line treatment of metastatic renal cell carcinoma (mRCC). Although the National Comprehensive Cancer Network (NCCN) guidelines offer physicians evidence-based recommendations for therapy, there are few real-world studies to help inform the utilization of these agents in clinical practice.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom